In a Complete Response Letter issued Monday, the FDA cited findings during a multi-sponsor inspection of Checkpoints third-party contract manufacturer that the company will need to address in its resubmission, Checkpoint said in a press release
By in situ hybridization and immunostaining, BPC 157 was found in gastrointestinal mucosa, lung bronchial epithelium, epidermal layer of the skin, and kidney glomeruli [10]
Given the scale of demand demand that is going to be met, if not by a state licensed compounding pharmacy, then by the black and gray markets we believe the lens that the FDA is using related to these peptides, at least some of the peptides, is the wrong lens, Brunner said
Using non-sterile equipment undermines the bacteriostatic protection